Medulloblastom
Özet
Medulloblastom, çocukluk çağının en sık karşılaşılan malign beyin tümörü olup santral sinir sisteminin agresif ve yüksek dereceli (Evre 4) embriyonel tümörleri arasında sınıflandırılmaktadır. Genellikle serebellum veya dördüncü ventrikül çevresinde lokalize olan bu tümör, anatomik yerleşimi nedeniyle obstrüktif hidrosefaliye yol açarak baş ağrısı, bulantı ve ataksi gibi intrakranial basınç artışı semptomlarıyla klinik olarak prezente olur. Teşhis ve evreleme süreçlerinde detaylı nörolojik muayenenin yanı sıra kontrastlı manyetik rezonans görüntüleme (MRG) ve beyin omurilik sıvısı (BOS) sitopatolojisi hayati önem taşımaktadır. Histopatolojik olarak klasik, desmoplastik/nodüler, yaygın nodülariteli ve büyük hücreli/anaplastik varyantlara ayrılan hastalık; günümüzde gen ekspresyon profillerine göre WNT-aktif, SHH-aktif, Grup 3 ve Grup 4 olmak üzere dört ana moleküler alt grupta incelenir. Bu moleküler sınıflama, hastaların risk stratifikasyonunu belirlemede en belirleyici faktör olup WNT grubu mükemmel bir prognoza işaret ederken, nüks ve metastaz eğilimi yüksek olan Grup 3 en kötü prognoza sahiptir. Tedavi yönetiminde temel strateji, maksimal güvenli cerrahi rezeksiyonu takiben kraniyospinal radyoterapi ve sistemik kemoterapiden oluşan kombine modalitelerin uygulanmasıdır. Güncel teknolojik gelişmeler ve risk gruplarına göre optimize edilen kemoradyoterapi rejimleri sayesinde uzun süreli sağkalım oranlarında kayda değer başarılar elde edilse de, tedavi sonrasında gelişebilecek geç dönem nörotoksik komplikasyonların yönetimi kritik bir önem arz etmektedir.
Medulloblastoma is the most prevalent malignant brain tumor in children, categorized as an aggressive, high-grade (Grade 4) embryonal tumor of the central nervous system. Primarily localized within the cerebellum or the fourth ventricle, its proximity frequently causes obstructive hydrocephalus, presenting clinically with symptoms of increased intracranial pressure such as headache, vomiting, and ataxia. Diagnostic and staging protocols heavily rely on comprehensive neurological examinations, contrast-enhanced magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) cytopathology to detect leptomeningeal dissemination. Histopathologically differentiated into classic, desmoplastic/nodular, extensively nodular, and large cell/anaplastic variants, contemporary medicine classifies the disease into four major molecular subgroups based on gene expression: WNT-activated, SHH-activated, Group 3, and Group 4. This molecular stratification serves as a pivotal prognostic determinant, where the WNT subgroup demonstrates an excellent survival outcome exceeding ninety percent, whereas Group 3 exhibits a highly aggressive metastatic nature and the poorest prognosis. The cornerstone of therapeutic management involves a multidisciplinary approach encompassing maximal safe surgical resection followed by craniospinal irradiation and adjuvant systemic chemotherapy. Although advanced surgical techniques and risk-adapted chemoradiotherapy regimens have remarkably improved long-term survival rates to approximately seventy-five percent, mitigating late-term toxic complications and preserving the quality of life remain critical challenges in patient survivorship.
Referanslar
McNeil DE, Coté TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER update. Medical and Pediatric Oncology. 2002;39(3):190-4.
Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. Journal of Clinical Neuroscience. 2012;19(11):1541-4.
Thorne RN, Pearson AD, Nicoll JA, Coakham HB, Oakhill A, Mott MG, et al. Decline in incidence of medulloblastoma in children. Cancer. 1994;74(12):3240-4.
Bourgouin PM, Tampieri D, Grahovac SZ, Léger C, Del Carpio R, Melançon D. CT and MR imaging findings in adults with cerebellar medulloblastoma: comparison with findings in children. AJR Am J Roentgenol. 1992;159(3):609-12.
Poretti A, Meoded A, Huisman TA. Neuroimaging of pediatric posterior fossa tumors including review of the literature. J Magn Reson Imaging. 2012;35(1):32-47.
Wolpert SM BP. MRI in Pediatric Neuroradiology, Mosby, St. Louis. 1992.
Kasantikul V, Shuangshoti S. Cerebellar medulloblastomas: a study of 35 cases with particular reference to cellular differentiation. Surgical neurology. 1986;26(6):532-41.
Hubbard JL, Scheithauer BW, Kispert DB, Carpenter SM, Wick MR, Laws ER. Adult cerebellar medulloblastomas: the pathological, radiographic, and clinical disease spectrum. Journal of neurosurgery. 1989;70(4):536-44.
D’Arco F, Khan F, Mankad K, Ganau M, Caro-Dominguez P, Bisdas S. Differential diagnosis of posterior fossa tumours in children: new insights. Pediatric Radiology. 2018;48(13):1955-63.
Koeller KK, Rushing EJ. From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. Radiographics. 2003;23(6):1613-37.
Poretti A, Meoded A, Huisman TA. Neuroimaging of pediatric posterior fossa tumors including review of the literature. Journal of magnetic resonance imaging. 2012;35(1):32-47.
Birch J, Marsden H, Jones PM, Pearson D, Blair V. Improvements in survival from childhood cancer: results of a population based survey over 30 years. Br Med J (Clin Res Ed). 1988;296(6633):1372-6.
Brandes AA, Franceschi E, Tosoni A, Reni M, Gatta G, Vecht C, et al. Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Critical reviews in oncology/hematology. 2009;71(2):165-79.
Mazloom A, Zangeneh AH, Paulino AC. Prognostic factors after extraneural metastasis of medulloblastoma. International Journal of Radiation Oncology* Biology* Physics. 2010;78(1):72-8.
Fouladi M, Gajjar A, Boyett JM, Walter AW, Thompson SJ, Merchant TE, et al. Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. Journal of clinical oncology. 1999;17(10):3234-7.
Terterov S, Krieger MD, Bowen I, McComb JG. Evaluation of intracranial cerebrospinal fluid cytology in staging pediatric medulloblastomas, supratentorial primitive neuroectodermal tumors, and ependymomas. Journal of Neurosurgery: Pediatrics. 2010;6(2):131-6.
Miralbell R, Bieri S, Huguenin P, Feldges A, Morin A, Garcia E, et al. Prognostic value of cerebrospinal fluid cytology in pediatric medulloblastoma. Annals of oncology. 1999;10(2):239-42.
Perek D, Perek-Polnik M, Drogosiewicz M, Dembowska-Bagińska B, Roszkowski M, Barszcz S. Risk factors of recurrence in 157 MB/PNET patients treated in one institution. Child's Nervous System. 1998;14(10):582-6.
MING-TAK HO D, HSU C-Y, CHIANG H, EBERHART CG, BURGER PC. Histopathologic grading of medulloblastomas. Authors' reply. Cancer. 2002;95(12):2577-9.
Orr BA. Pathology, diagnostics, and classification of medulloblastoma. Brain Pathology. 2020;30(3):664-78.
Katsetos CD, Liu HM, Zacks SI. Immunohistochemical and ultrastructural observations on Homer Wright (neuroblastic) rosettes and the “pale islands” of human cerebellar medulloblastomas. Human pathology. 1988;19(10):1219-27.
McLendon R, Friedman H, Fuchs H, Kun L, Bigner S. Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study. Histopathology. 1999;34(2):154-62.
Kozmik Z, Sure U, Rüedi D, Busslinger M, Aguzzi A. Deregulated expression of PAX5 in medulloblastoma. Proceedings of the National Academy of Sciences. 1995;92(12):5709-13.
Yokota N, Aruga J, Takai S, Yamada K, Hamazaki M, Iwase T, et al. Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer research. 1996;56(2):377-83.
Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta neuropathologica. 2016;131(6):803-20.
Sure U, Berghorn W, Bertalanffy H, Wakabayashi T, Yoshida J, Sugita K, et al. Staging, scoring and grading of medulloblastoma. Acta neurochirurgica. 1995;132(1):59-65.
McManamy CS, Pears J, Weston CL, Hanzely Z, Ironside JW, Taylor RE, et al. Nodule formation and desmoplasia in medulloblastomas—defining the nodular/desmoplastic variant and its biological behavior. Brain Pathology. 2007;17(2):151-64.
Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol. 2011;29(29):3852-61.
Leonard JR, Cai DX, Rivet DJ, Kaufman BA, Park T, Levy BK, et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. Journal of neurosurgery. 2001;95(1):82-8.
Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer. 2002;94(2):552-60.
McManamy CS, Lamont JM, Taylor RE, Cole M, Pearson AD, Clifford SC, et al. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. Journal of Neuropathology & Experimental Neurology. 2003;62(6):627-32.
Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. Journal of clinical oncology. 2011;29(11):1408.
Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta neuropathologica. 2012;123(4):473-84.
Northcott PA, Shih DJ, Peacock J, Garzia L, Sorana Morrissy A, Zichner T, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012;488(7409):49-56.
Cho Y-J, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of Clinical Oncology. 2011;29(11):1424.
Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, Van Sluis P, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PloS one. 2008;3(8):e3088.
Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. Journal of clinical oncology. 2006;24(12):1924-31.
Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta neuropathologica. 2011;121(3):381-96.
Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012;488(7409):106-10.
Taylor MD, Northcott PA, Korshunov A, Remke M, Cho Y-J, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta neuropathologica. 2012;123(4):465-72.
Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, et al. Adult medulloblastoma comprises three major molecular variants. Journal of clinical oncology. 2011;29(19):2717-23.
Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. The Lancet Oncology. 2018;19(6):785-98.
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. Journal of Clinical Oncology. 2013;31(23):2927.
Zhao F, Ohgaki H, Xu L, Giangaspero F, Li C, Li P, et al. Molecular subgroups of adult medulloblastoma: a long-term single-institution study. Neuro Oncol. 2016;18(7):982-90.
Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011;29(19):2717-23.
Smyth I, Narang MA, Evans T, Heimann C, Nakamura Y, Chenevix-Trench G, et al. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet. 1999;8(2):291-7.
Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19(6):785-98.
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013;31(23):2927-35.
Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473-84.
Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014;25(3):393-405.
Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012;148(1-2):59-71.
Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12(12):818-34.
Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29(11):1408-14.
Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29(11):1424-30.
Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017;547(7663):311-7.
Eran A, Ozturk A, Aygun N, Izbudak I. Medulloblastoma: atypical CT and MRI findings in children. Pediatr Radiol. 2010;40(7):1254-62.
Koral K, Gargan L, Bowers DC, Gimi B, Timmons CF, Weprin B, et al. Imaging characteristics of atypical teratoid-rhabdoid tumor in children compared with medulloblastoma. AJR Am J Roentgenol. 2008;190(3):809-14.
Rutkowski S, von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol. 2010;28(33):4961-8.
Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol. 2011;29(11):1400-7.
Jenkin D, Shabanah MA, Shail EA, Gray A, Hassounah M, Khafaga Y, et al. Prognostic factors for medulloblastoma. Int J Radiat Oncol Biol Phys. 2000;47(3):573-84.
Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131(6):821-31.
Chang CH, Housepian EM, Herbert C, Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology. 1969;93(6):1351-9.
Franceschi E, Giannini C, Furtner J, Pajtler KW, Asioli S, Guzman R, et al. Adult Medulloblastoma: Updates on Current Management and Future Perspectives. Cancers (Basel). 2022;14(15).
Kunschner LJ, Kuttesch J, Hess K, Yung WK. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol. 2001;3(3):167-73.
Chan AW, Tarbell NJ, Black PM, Louis DN, Frosch MP, Ancukiewicz M, et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery. 2000;47(3):623-31; discussion 31-2.
Schneider C, Ramaswamy V, Kulkarni AV, Rutka JT, Remke M, Tabori U, et al. Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery. J Neurosurg Pediatr. 2015;15(3):236-42.
Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery. 1996;38(2):265-71.
Park TS, Hoffman HJ, Hendrick EB, Humphreys RP, Becker LE. Medulloblastoma: clinical presentation and management. Experience at the hospital for sick children, toronto, 1950-1980. J Neurosurg. 1983;58(4):543-52.
Koeller KK, Rushing EJ. From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. Radiographics. 2003;23(6):1613-37.
Yilmaz H, Akcay E, Benek HB. Medulloblastoma in Adults: Surgical Outcomes and Survival - A Single Center Analysis of 16 Patients. Turk Neurosurg. 2021;31(6):980-5.
BOLAT E, TURHAN T. Medulloblastomada Tedavi Seçenekleri. Türk Nöroşirürji Dergsi. 2017;27(1):31-7.
Lannering B, Rutkowski S, Doz F. Standard risk medulloblastoma: hyperfractionated vs conventional radiotherapy followed by chemotherapy. Results from the randomized multicenter study HIT-SIOP PNET 4. J Clin Oncol. 2012;26:3187-93.
Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. International Journal of Radiation Oncology* Biology* Physics. 2002;52(3):599-605.
Yuh GE, Loredo LN, Yonemoto LT, Bush DA, Shahnazi K, Preston W, et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. The Cancer Journal. 2004;10(6):386-90.
Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. Journal of neurosurgery. 1994;81(5):690-8.
Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. Journal of clinical oncology. 1999;17:2127-36.
Friedrich C, von Bueren AO, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, et al. Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. European journal of cancer. 2013;49(4):893-903.
Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. Journal of clinical oncology. 2012;30(26):3187-93.
Franceschi E, Bartolotti M, Paccapelo A, Marucci G, Agati R, Volpin L, et al. Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients? Journal of neuro-oncology. 2016;128(2):235-40.
Brandes AA, Franceschi E, Tosoni A, Blatt V, Ermani M. Long‐term results of a prospective study on the treatment of medulloblastoma in adults. Cancer. 2007;110(9):2035-41.
Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, et al. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-oncology. 2017;19(2):259-69.
